An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine

[1]  J. Taylor‐Papadimitriou,et al.  MUC1 immunotherapy. , 2010, Immunotherapy.

[2]  V. Hespanhol,et al.  MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features. , 2009, Veterinary journal.

[3]  P. DeInnocentes,et al.  Phenotype‐rescue of cyclin‐dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer , 2009, Journal of cellular biochemistry.

[4]  D. Curiel,et al.  An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. , 2008, Veterinary immunology and immunopathology.

[5]  W. Misdorp,et al.  Tumors of the Mammary Gland , 2008 .

[6]  H. Asanuma,et al.  T‐Helper (Th) 1/ Th2 Imbalance in the Peripheral Blood of Dogs with Malignant Tumor , 2007, Microbiology and immunology.

[7]  M. Day.  Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. , 2007, Veterinary parasitology.

[8]  G. Mulcahy,et al.  Evaluation of Th1-like, Th2-like and immunomodulatory cytokine mRNA expression in the skin of dogs with immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis. , 2006, Veterinary dermatology.

[9]  P. DeInnocentes,et al.  Expression and sequence of canine SIRT2 and p53 genes in canine mammary tumour cells - effects on downstream targets Wip1 and p21/Cip1. , 2006, Veterinary and comparative oncology.

[10]  P. DeInnocentes,et al.  Alterations in CDK1 expression and nuclear/nucleolar localization following induction in a spontaneous canine mammary cancer model , 2006, Journal of cellular biochemistry.

[11]  T. Ohno,et al.  Cancer immunotherapy using dendritic/tumour‐fusion vaccine induces elevation of serum anti‐nuclear antibody with better clinical responses , 2006, Clinical and experimental immunology.

[12]  A. Loukas,et al.  Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs. , 2006, Vaccine.

[13]  M. Atkins,et al.  Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses , 2004, Clinical Cancer Research.

[14]  P. DeInnocentes,et al.  Characterization of the CDP-like/CTAS-1 binding site in the okadaic acid response element (OARE) of the human CDK1(p34cdc2) promoter. , 2004, Anticancer research.

[15]  E. Macewen,et al.  Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment , 1990, Cancer and Metastasis Reviews.

[16]  J. Raynaud,et al.  Animal models for hormone-dependent human breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[17]  P. Boag,et al.  Characterisation of humoral immune responses in dogs vaccinated with irradiated Ancylostoma caninum. , 2003, Veterinary immunology and immunopathology.

[18]  L. H. Carvalho,et al.  IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages , 2002, Nature Medicine.

[19]  H. J. Baker,et al.  CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. , 2002, Veterinary immunology and immunopathology.

[20]  Joanna S Morris,et al.  Small Animal Oncology , 2001 .

[21]  E. Gilboa,et al.  Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1 , 2001, The Journal of Immunology.

[22]  T. Ohno,et al.  Antitumor Effect of Immunizations With Fusions of Dendritic and Glioma Cells in a Mouse Brain Tumor Model , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[23]  S. Wagner,et al.  Management of malignant melanoma: new developments in immune and gene therapy , 2000, Clinical and experimental dermatology.

[24]  E. Wagner,et al.  Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice , 2000, Cancer Gene Therapy.

[25]  Salgaller Ml.  American Association for Cancer Research: dendritic cells: strategies and vaccines. April 1-5, 2000, San Francisco, CA, USA. , 2000 .

[26]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[27]  A. Dalgleish,et al.  Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. , 2000, Biochimica et biophysica acta.

[28]  D. Kufe,et al.  Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Walden.  Hybrid cell vaccination for cancer immunotherapy. , 2000, Advances in experimental medicine and biology.

[30]  H. O’Neill,et al.  Dendritic Cell Immunotherapy for Melanoma , 1999 .

[31]  H. O’Neill,et al.  Review: dendritic cell immunotherapy for melanoma. , 1999, Cancer biotherapy & radiopharmaceuticals.

[32]  S. Nair.  Immunotherapy of cancer with dendritic cell-based vaccines , 1998, Gene Therapy.

[33]  W. Morrow,et al.  Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model , 1998, Gene Therapy.

[34]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[35]  J. Timmerman,et al.  Melanoma vaccines: Prim and proper presentation , 1998, Nature Medicine.

[36]  U. Trefzer,et al.  Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti tumour cytotoxic T cells. , 1998, Advances in experimental medicine and biology.

[37]  R. Steinman,et al.  Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.

[38]  Steinman Rm.  Dendritic cells and immune-based therapies. , 1996 .

[39]  R. C. Bird,et al.  Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. , 1996, American journal of veterinary research.

[40]  E. Sartin,et al.  Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and sensitivity to tamoxifen and doxorubicin. , 1993, Anticancer research.

[41]  R. Henderson,et al.  Biologic properties of cell lines derived from canine mammary carcinomas. , 1986, Journal of the National Cancer Institute.

[42]  D. Taylor,et al.  Factors influencing canine mammary cancer development and postsurgical survival. , 1969, Journal of the National Cancer Institute.

[43]  I Iu IUDIN,et al.  [Tumors of the mammary gland]. , 1955, Meditsinskaia sestra.